Author

Stella Williams

Institution: Clatterbridge Cancer Centre NHS Foundation Trust

Observed institution: Clatterbridge Cancer Centre NHS Foundation Trust

ORCID: 0009-0002-5202-5253

Observed ORCID: 0009-0002-5202-5253

OpenAlex ID: A5108981220

A Comparative Analysis of Cardiovascular Events Associated With Acalabrutinib Versus Ibrutinib in Chronic Lymphocytic Leukemia: Insights From a Global Federated Network

2025 · Abdulrahman Majrashi, Ying X. Gue, et al. · Pharmacology Research & Perspectives · 6

Ibrutinib-Related Uveitis: A Case Series from Two Tertiary Centres in the United Kingdom

2024 · Hagar Ibrahim, Chung Shen Chean, et al. · Ocular Immunology and Inflammation · 4

Effect of age and sex on cardiovascular outcomes among patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors: a propensity matched analysis

2026 · Abdulrahman Majrashi, Alena Shantsila, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2

Differential Cardiotoxicity of Ibrutinib Versus Chemoimmunotherapy in Chronic Lymphocytic Leukemia: A Population-Based Study

2024 · Abdulrahman Majrashi, Ying X. Gue, et al. · Journal of Clinical Medicine · 1

Trends and socio‐economic disparities in chronic lymphocytic leukaemia 2014–2022: An England‐wide cohort study from the UNCOVER group

2026 · Temitope Erinfolami, Amelia Fisher, et al. · British Journal of Haematology

Acalabrutinib monotherapy as a first-line treatment for CLL: 3-year follow-up of the real-world EPIC study

2026 · Toby A. Eyre, Nicolas Martinez-Calle, et al. · Blood Advances

Works count: 6

Citation count: 13

H-index: 2

I10-index: